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A b s t r a c t  
It is commonly recognized in the pharmaceutical industry that on average more than 40% of newly 
discovered drug candidates are poorly water-soluble. The objective of present research is to explore 
the application of mixed solvency technique in the injection formulation of poorly soluble drugs and 
to reduce concentration of individual solubilizers (used for solubility enhancement) to minimize the 
toxic effects of solubilizers. In the present work poorly soluble drugs Ofloxacin are selected as model 
drugs. Ofloxacin is an antibiotic drug tried to formulate the aqueous injection by the use of various 
physiologically compatible solubilizing agent like Lignocaine Hydrochloride, Niacinamide, Sodium 
benzoate, Sodium citrate, PEG 400, PEG 4000, PVP 40000, Ethanol, and Propylene Glycol. For 
expected synergistic enhancement effect on solubility of these poorly soluble drugs various blends 
of solubilizers shall be tried to decrease the amounts of Solubilizer employed for a desired solubility 
enhancement ratio. The study further opens the chances of preparing dry powders for injection of 
drug which are not stable in aqueous solution, ready to use injection. 
Keywords: Mixed solvency solubilization, Ofloxacin, solubility enhancement, synergistic 
enhancement effect. 
 
 
Introduction 
Parenteral dosage forms and delivery systems include injectables 
(i.e., solutions, suspensions, emulsions, and dry powders for 
reconstitution), intramammary infusions, intravaginal delivery 
systems, and implants. Maheshwari proposed the concept of mixed 
solvency. He is of the opinion that all substances whether liquids, 
gases or solids possess solubilizing power and hence concentrated 
aqueous solution containing various dissolved substances can also 
improve the solubility of poorly water soluble drugs. In 
pharmaceutical science, solubility is commonly related to the 
bioavailability of the compound of interest, especially for poorly 
soluble compounds. Slow absorption rate result in an erratic and 
variable profile of drug level. Administration of a drug in any 
dosage form, except solution involves a dissolution step. Most co-
solvent has hydrogen bond donor and or acceptor groups as well 
as small hydrocarbon regions. Their Hydrophilic hydrogen bonding 
groups ensure water miscibility while their hydrophobic 
hydrocarbon regions interfere with water hydrogen bonding 
network, reducing the overall intermolecular attraction of water. By 
disrupting waters self-association, co-solvent reduces water ability 
to squeeze out non-polar, hydrophobic compounds, thus increasing 
solubility [1-7]. 
Materials & Method  
Ofloxacin was obtained from Enicar Pvt. Ltd. Bhoisar Niacinamide 
was obtained from Morden Lab Ltd. Indore, Lignocaine 
Hydrochloride, Sodium Benzoate, Sodium Citrate, PEG 400, PEG 
4000, PVP 40000, Ethanol, Propylene glycol was obtained from S 
D fine chemicals, Mumbai. [8,9] 
 
Method of Preparation 
 
Preparation of Calibration curve in distilled water 
10 mg of Ofloxacin wt. & transferred in to volumetric flask by 
addition of distilled water and volume made up to 100 ml Distilled 
water so as obtained solution 100 ppm . Concentration range 2 to 
10 ppm. Absorbance of these solutions was measured on double 
beam UV visible spectrophotometer at 200 nm to 400 nm against 
distilled water and spectrum is shown in fig no. 1, Linearity graph 
shown fig no. 2 and absorbance recorded in table no. 1[10,11] 
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Figure 1: Calibration curve at 287.6nm 
 
 
Figure 2:  Linearity curve 
 
 
 
 
 
Table 1 Absorbance recorded  
ppm solution Absorbance at 287.6nm
2 ppm 0.134
4 ppm 0.275
6 ppm 0.415
8 ppm 0.564
10 ppm 0.670
 
FT-IR Spectroscopy study Drug & Solubilizers 
About 1-5 mg of Ofloxacin drug sample was triturated with 
approximately 300 mg of dry, finely potassium bromide IR and 
compressed as pellet & spectra was recorded for pure drug shown 
in fig. no. 3. And Ofloxacin with Solubilizer was combination 1:1 
mix then finally powdered KBr IR compressed as pellet and spectra 
was recorded for drug and Solubilizer shown fig. no. 4 to 9.[12,13] 
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      Figure 5: FT-IR Spectrum of Ofloxacin with Niacinamide. 
 
 
      Figure 6: FT-IR Spectrum of Ofloxacin with Sodium Citrate 
 
 
      Figure 7: FT-IR Spectrum of Ofloxacin With PEG-4000 
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               Figure 8: FT-IR Spectrum of Ofloxacin with PVP 40000 
 
      Figure 9: FT-IR Spectrum of Ofloxacin with Sodium Benzoate 
 
DSC of Drug Sample 
Sample of 2-5 mg of the pure Ofloxacin or the above-mentioned 
sample was sealed in Al. Pans at constants heating rate of 
100C/min. in scanning temp. Range of 30 to 3000C. The DSC 
spectrum of Ofloxacin drug sample in fig. no. 10. 
 
Figure 10: DSC Thermogram of Ofloxacin 
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Physical Stability of Drug & Solubilizers 
 
The compatibility of drug the solubilizers was assesses by drug-
solubilizers interaction studies. The drug mixed with excipients in 
1:1 (50 mg) in separate glass vials which were then properly 
sealed 7 kept undisturbed at different condition storage condition at 
room temp., 400C, & in refrigerator for period of one month. The 
observation was recorded in given table no. 2.[17] 
 
Table 2: Observations of Drug-excipients Interaction Study 
Sr. No.
Drug-Excipients 
Mixture Initial Appearance 
Storage conditions 
Refrigerator (2-
8ÀC) Room Temperature 40ÀC 
Weeks Weeks Weeks 
1 2 3 4 1 2 3 4 1 2 3 4
1 OFLOX. White powder N N N N N N N N N N N N 
2 OFLOX+PEG 4000 Colorless solid 
powder 
N N N N N N N N N N N N 
3 OFLOX+LH 
Colorless solid 
powder N N N N N N N N N N N N 
4 OFLOX +SB Colorless solid powder N N N N N N N N N N N N 
5 OFLOX +SC 
Colorless solid 
powder N N N N N N N N N N N N 
6 OFLOX +PVP-FT Colorless solid powder N N N N N N N N N N N N 
7 OFLOX +NM 
Colorless solid 
powder N N N N N N N N N N N N 
OFOLX   = Ofloxacin                                                      N          = No Change 
LH          = Lignocaine hydrochloride                             NM        = Niacinamide 
SB          = Sodium benzoate                                         PVP-FT = PVP-40000 
SC          = Sodium citrate 
 
 
Solubilization Study in Distilled water and Drug in 
Aqueous Solution Containing Individual Solubilizers 
(25% w/v) 
 
 Solubility of Ofloxacin in distilled water was determined by shake 
flask method. About 5 ml distilled water taken in three vials of 10 ml 
capacity separately, to each vials an excess amount of Ofloxacin 
was added then 10 min for proper mixing. They were kept in orbital 
flask shaker maintained at 250C for 12 hrs. The solution was then 
allowed to equilibrilate for 24hrs. Then solution containing 
excesses undissloved drug were transferred in to centrifuge tubes 
and centrifuges at 2000 rpm for 10 min. & supernatant was filtered 
through Whatman filter paper # 41. Filtrate was suitably diluted with 
distilled water and analyzed using double beam UV visible 
spectrophotometer at fixed wavelength at 287.6 nm against 
distilled water. And all individual (25% w/v) solubilizersÊ procedure 
as same above result recorded in table no. 3 & shown in fig. no. 
11[9]. 
 
Solubility Determination of Drug in Aqueous Solution 
Mixed Blend Solubilizers (25% w/v)9 
 
For the preparation of mixed blends (aqueous solutions) containing 
solubilizers, required amount of individual solubilizers were 
weighed and transferred to volumetric flask of 10 ml capacity 
containing seven ml of distilled water, to this the solubilizers were 
added and flask was shaken vigorously to dissolve to added 
solubilizers. After complete dissolution of solubilizers the volume 
was made up to the mark with distilled water, flask was shaken 
again to get homogenous solution. The prepared blends were 
filtered and used for further solubilization studies. Mixed Blend 
shown in table no.4 & 5 and solubility ratio fig no. 12. 
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Table 3: SolubilityÊs of Ofloxacin in Aqueous Solutions Containing Individual Solubilizers 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Solubility Profile of Ofloxacin in Aqueous solution of 
Individual solubilizers 25% w/v 
Determination of pH Dependent Solubility of Drug 
The USP buffer solution of pH 2.4, 5.6, 6.8, 7.4, & 9 were prepared 
& pH of this solution was adjusted digital pH meter. About 5 ml 
each buffer solution was taken in vials separately. Then excess 
amount of Ofloxacin was added then 10 min. for proper mixing. 
They kept in orbital flask shaker maintained at 250C for 12 hrs. The 
solution was then allowed to equilibrate for 24 hrs. , solution 
containing excess undissloved drug transferred in to centrifuge 
tubes and centrifuged at 2000 rpm for 10 min. & supernatant was 
filtered through Whatman filter paper # 41. Filtrate was suitably 
diluted using distilled water and analyzed using UV visible  
 
 
 
 
spectrophotometer at fixed wavelength at 287.6 nm against 
respective reagent blanks. Result obtained in table no. 6 & fig. no. 
13.[9]. 
Chromatographic Study of Solubilized Drug product 
A plate of silica gel GF 254 was activated at 110 for 1 hr. and used.  
The Methanolic solution of Ofloxacin alone & drug & solubilizers as 
Blend 19, 21, 22 & 23 Then, the plate was left in air for 10 min. to 
dry and transferred to solvent jar saturated with solvent system 
was allowed to run for about 4.2 cm. finally, The plate was left in air 
10 min. to dry and transferred to solvent jar saturated with solvent 
system composed of mixture of chloroform and methanol 1:1 v/v. 
Finally plate was transferred to an oven maintained at temp. 800C 
for 2 min. & observed in UV chamber at short wavelength for 
visualization of spots. In order to predict the possible interaction or 
Complexation between drug and solubilizers the TLC studies were 
performed. The Rf values were determined & recorded in table no. 
7 [14]. 
Optimization of Blend for preparation of injection 
On the basis of result obtained from solubility studies, mixed 
blends in which solubility of Ofloxacin was more than 4 mg/ml and 
in all 4 blend contained no Sodium benzoate & Lignocaine HCl. 
Due presence of Precipitate , such selected blend were  B-19, B-
21, B-22, B-23. To develop 1 ml of Ofloxacin injection, amount of 
solubilize and drug that will be administered through each mixed 
blend was determined. The proposed formulations are shown in 
table no. 8 to 11. 
 
 
 
 
0 10 20 30 40 50
Sodium benzoate
Tween 20
Niacinamide
Lignocaine hydrochloride
PEG 4000
Propylene glycol
PEG 400
PVP-40000
Ethanol
Distilled water
Solubility mg/ml
Aqueous solution of solubilizers 
(25% w/v) 
Equilibrium solubility of 
Ofloxacin (mg/ml) 
Solubility enhancement 
Ratio 
Distilled water 0.11  
PEG 4000 2.55 23.18 
PEG 400 1.97 17.90 
Tween 20 3.98 36.18 
Niacinamide 3.25 29.54 
Propylene glycol 2.28 20.72 
PVP-40000 1.69 15.36 
Ethanol 1.55 14.09 
Sodium benzoate 4.75 43.18 
Lignocaine hydrochloride 2.66 24.18 
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Table 4: Preparation of Mixed Blend 25% w/v of solubilizers 
Blend 
No. 
Lignocaine HCl Niacinami
de 
Sodium 
Benzoate 
PEG 
400 
PEG 
4000 
PVP 
40000 
Propylene 
glycol 
Sodium 
citrate 
Tween 
20 
Ethanol
B-1 6.25 - 6.25 6.25 6.25 - - - - -
B-2 6.25 6.25 - 6.25 6.25 - - - - -
B-3 6.25 6.25 6.25 6.25 - - - - - -
B-4 6.25 6.25 6.25 6.25 - - - - - -
B-5 5 5 5 5 5 - - - - -
B-6 - 6.25 6.25 6.25 6.25 - - - - -
B-7 6 6 - 5 5 - - 3 - -
B-8 6 - 6 5 5 - - 3 - --
B-9 6 5 4 6 2 - 2 - - -
B-10 6 6 6 - 5 - 2 - - -
B-11 8 2 8 2 - - 5 - - -
B-12 6 - 6 6 - - 7 - -- -
B-13 8 - - 8 - - 9 - - -
B-14 8 8 1 8 - - - - - -
B-15 5 6 4 5 - - - - 5 -
B-16 - 5 - 5 5 - 5 - 5 -
B-17 4 5 4 4 - - - 4 4
B-18 5 5 3 - - 3 5 - - 4
B-19 5 5 - 5 5 - - - - 5
B-20 5 5 5 5 - - - - - 5
B-21 5 5 - 5 4 3 - - - 3
B-22 - 5 5 5 - 5 5 - - -
B-23 5 5 - - 5 4 3 - - 3
B-24 5 - 5 - 5 5 5 - - -
 
Formulation of Aqueous Injection 
 i) Preparation of Blend: Every ingredient for each blend as 
mentioned in table no. 8 to 11 were accurately weighed & 
transferred in 25 ml volumetric flask. 20 ml of water for injection 
was added to flask was shaken to dissolve the content. Then 
volume was made up to 25 ml. 
ii) Preparation of Aqueous solution of Ofloxacin: For preparation of 
aqueous solution of Ofloxacin about 20 ml of Hydrotropic Blend 
solution was taken in 25 ml volumetric flask. Weighed amount of 
Ofloxacin was transferred in to volumetric flask. & flask was shaken 
until complete Dissolution of drug. Volume made up to 25 ml. to 
Shaken to get Homogeneous solution. 
iii) Treatment of packaging material: Glass vials were first washed 
three times with distilled water. All these vials were dried in an 
oven and sterilized by dry heating in an oven at 160ĈC for 2 hrs in 
inverted position. Rubber closures and aluminum seals used for 
plugging the vials were first washed several times with distilled 
water and then autoclaved at 15 lbs pressure (121ĈC) for 20 
minutes and finally dried in oven. 
iv) Preparation of aseptic area: The walls and floor of aseptic room 
were thoroughly washed with filtered tap water followed by 5% 
phenol solution. The room was fumigated using a mixture of 
formaldehyde and potassium permanganate. The laminar air flow 
bench was cleaned ad wiped out with 70% ethanol solution and 
switched on UV light was for 30 min. prior to filling of injection in to 
vials.   
v) Aseptic filtration:  The Aqueous solution of Ofloxacin was 
prepared as above & sterilized by filtration under the Membrane 
filter 0.22 øm (Millipore) was used for the filtration. The membrane 
filtration assembly fitted with the membrane filter was sterilized 
previously in the autoclave at 121ĈC and 15 lbs pressure for 20 
min. 
 
Evaluation of injection 
 
i) Appearance and colour of formulation15 
In which Appearance of Aqueous Injection of Ofloxacin show in 
Fig. no   , and colour of aqueous injection. Result recorded in table 
no. 12. 
ii)  Determination of pH of the developed aqueous injection9 
The pH of prepared formulations was determined using digital pH 
meter. The pH so obtain were recorded in table no. 12. 
iii) Accelerated stability studies17 
As soon as the product is developed, it is subjected to ageing; as a 
result its physical properties, chemical composition and even its 
biological availability may be changed. The prepared formulations  
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Table 5: blends 
 
Table 6: SolubilityÊs of Ofloxacin in buffer solutions of different pH  
 
 
 
 
 
 
 
 
 
 
were subjected to 2-8 0C, 25 0C, 40 0C and 55 0C to observe the 
stability of medicament in developed formulations. Samples were 
withdrawn at interval of 7 days, suitably diluted with distilled water 
and analyzed using UV/Visible spectrophotometer against 
respective reagent blanks at fixed wavelength 287.6 nm to 
determine the amount of drug remaining in formulation. The initial 
drug content in the formulation was taken as 100%. Percent drug 
remained at definite time intervals were recorded in table no. 13 to 
16 & degradation curve shown in fig no. 15 to 18. 
iv) Clarity testing of aqueous injection15 
Clarity test of Aqueous injection product was performed by visually 
inspecting the externally clean vial under a good light, baffled 
against reflection into the eyes, and viewed against black and white 
background, with the content set in swirling motion. The results so 
obtained are shown in table no. 12. 
v) Leakage test of aqueous formulation15 
The methylene blue solution was prepared 1% then all vials 
emerged in solution for few min. then check leakage test for 
formulation, the results so obtained are shown in table no. 12.  
vi) Viscosity of aqueous injection11 
The Brookfield Helipath Stand is designed to slowly lower or raise 
a Brookfield Viscometer/Rheometer so that its rotating T-bar  
 
 
 
Figure. 12: Equilibrium solubility data of Ofloxacin in various blends 
 
0 20 40 60
B‐1
B‐2
B‐3
B‐4
B‐5
B‐6
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B‐8
B‐9
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B‐11
B‐12
B‐13
B‐14
B‐15
B‐16
B‐17
B‐18
B‐19
B‐20
B‐21
B‐22
B‐23
B‐24
(Solubility mg/ml)
Solubility enhancement ratio
Blend codes Solubility (mg/ml) Solubility enhancement 
ratio 
B-1 1.112 10.10 
B-2 1.612 14.65 
B-3 2.312 21.01 
B-4 2.229 20.26 
B-5 1.787 16.24 
B-6 1.578 14.34 
B-7 1.732 15.74 
B-8 1.280 11.63 
B-9 1.633 14.84 
B-10 1.834 16.67 
B-11 1.922 17.47 
B-12 2.510 22.81 
B-13 3.156 31.96 
B-14 4.430 40.27 
B-15 4.221 38.37 
B-16 3.321 30.19 
B-17 4.767 42.33 
 B-18 2.157 19.60 
B-19 2.589 23.53 
B-20 2.540 23.09 
B-21 5.273 47.93 
B-22 4.680 42.54 
B-23 4.178 37.98 
B-24 3.341 30.37 
Buffer (pH) Solubility (mg/ml) 
2.4 0.94 
5.6 0.81 
6.8 0.74 
7.4 0.66 
9 0.52 
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spindle will describe a helical path through the test sample. By 
always cutting into fresh material, the problem of channeling or 
separating is eliminated and meaningful viscosity/consistency  
 
 
                                                                                                         
Figure 13: pH Dependent Solubility Profile of Ofloxacin 
 
measurements can be made. The automatic reversing feature of 
the Helipath Stand allows measurements to be made over a 
variable period of time. 
 
Table 7:   RF Values of Ofloxacin 
Solvent system Adsorbent RF  value 
 
 
Chloroform: 
methanol   (1:1) 
 
Silica gel 
GF 254 
Ofoxs. B-21 B-22 B-23 
0.56 0.57 0.54 0.59
Procedure 
1) Prepared formulation of Aqueous Injection Ofloxacin of various 
Blend 19, 21, 22, 23  
2) This injection taken in 50 ml beaker. 
3) To measure viscosity by using 96 S spindle no. at 5 rpm. and 
results obtained in table no. 12.  
4) Sterility test for aqueous injection as per I.P.15 
The test for sterility is intended for detection and presence of viable 
form of micro-organism is a pharmaceutical preparation the test 
tube must be carried out under condition designed to avoid 
accidental contamination during test.  
 
Table 8: Formulation B-21 
Sr. 
No. 
 
Ingredients Formula for 
5.27mg/1ml batch 
 
Formula for
131.75mg/25 
ml batch 
1 Ofloxacin 5.27mg 0.131g
2 Lignocaine hydrochloride 0.05g 1.25g
3 Ethanol 0.03g 0.75g
4 Niacinamide 0.05g 1.25g
5 PEG 400 0.05g 1.25g
6 PEG 4000 0.04g 1g
7 PVP-40000 0.03g 0.75g
8 Sterile water for injection Up to 1ml Up to 25ml
Membrane filtration 
 Use membrane filters 50 mm in diameter and having a nominal 
pore size of not greater than 0.45 μm the effectiveness of which in 
retaining bacteria has been established for the type of preparation 
under examination. Transfer 10 ml or a quantity of each dilution 
containing 1 g of the preparation under examination to each of two 
membrane filters and filter immediately. Wash each membrane by 
filtering through it three or more successive quantities, each of 
about 100 ml, of a suitable liquid such as buffered sodium chloride-
peptone solution pH 7.0. Transfer one of the membrane filters, 
intended for the enumeration of bacteria, to the surface of a plate 
of medium 2 and the other, intended for the enumeration of fungi, 
to the surface of a plate of medium 3. Incubate the plates for 5 
days, unless a more reliable count is obtained in shorter time, at 
30Ĉ to 35Ĉ in the test for bacteria and 20Ĉ to 25Ĉ in the test for fungi. 
Count the number of colonies that are informed. Calculate the 
number of micro-organisms per g or per ml of the preparation 
under examination, if necessary counting bacteria and fungi 
separately. 
 
Table 9:   Formulation B-19 
Sr. 
No. 
 
Ingredients Formula for
2.58mg/1ml batch 
Formula for
64.5mg/25 ml 
batch 
1 Ofloxacin 2.58mg 0.0645g
2 Lignocaine hydrochloride 0.05g 1.25g
3 Niacinamide 0.05g 1.25g
4 PEG 400 0.05g 1.25g
5 PEG 4000 0.05g 1.25g
6 Ethanol 0.05g 1.25g
7 Sterile water for injection Up to 1ml Up to 25ml
 
Pour-plate method 
For bacteria · Using Petri dishes 9 to 10 cm in diameter, add to 
each dish a mixture of 1 ml of the pretreated preparation and about 
15 ml of a liquefied casein Soyabean digest agar such as medium 
2, at not more than 45À. Alternatively, spread the pretreated 
preparation on the surface of the solidified medium in a Petri dish 
of the same diameter. If necessary dilute the pretreated 
preparation as described above so that a colony count of not more 
than 300 may be expected. Prepare at least two such Petri dishes 
using the same dilution and incubate 30Ĉ to 35Ĉ for 4 days, unless a 
more reliable count is obtained in a shorter time. Count the number 
colonies that are formed. Calculate the results using plates with the 
greatest number of colonies but taking 300 colonies per plate as 
the maximum consistent with good evaluation.  
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Table 10: Formulation B- 22 
Sr. 
No. 
 
Ingredients Formula for 
4.68mg/1ml 
batch 
Formula for
117mg/25ml 
batch 
1 Ofloxacin 4.68mg 0.117g
2 Propylene glycol 0.05g 1.25g
3 Sodium benzoate 0.05g 1.25g
4 PEG 400 0.05g 1.25g
5 Niacinamide 0.05g 1.25g
6 PVP-40000 0.05g 1.25g
7 Sterile water for injection Up to 1ml Up to 25ml
Table 11: Formulation B-23 
Sr. 
No. 
 
Ingredients Formula for 
4.17mg/1ml 
batch 
 
Formula for
104.25mg/25ml 
batch 
1 Ofloxacin 4.17mg 0.104g
2 Lignocaine hydrochloride 0.05g 1.25g
3 Niacinamide 0.05g 1,25g
4 PEG 4000 0.05g 1.25g
5 Propylene glycol 0.03g 0.75g
6 PVP 40000 0.04g 1g
7 Ethanol 0.03g 0.75g
8 Sterile water for injection Up to 1ml Up to 25ml
 
 
 Figure 14 Photographs of Aqueous Injections 
 
For fungi · Proceed as described in the test for bacteria but use 
Sabouraud dextrose agar with antibiotics such as medium 3 in 
place of medium 2 and incubate the plates at 20Ĉ to 25Ĉ for 5 days, 
unless a more reliable count is obtained in a shorter time. Calculate 
the results using plates with not more than 100 colonies. Result 
shown in table no. 17 & 18.  
Result and Discussion 
Calibration curve in distilled water 
The UV visible of Ofloxacin showed peak at 287.6 nm, which is 
same as reported in literature shown fig. no. 1 & absorbance 
recorded in table no. 1   From the calibration curve equation is 
given as y = 0.136x + 0.003. The value of R2 is 0.997. On the basis 
of obtained result it was concluded that Ofloxacin, Obeyed Beers 
Lamberts law in the range of 2 øg/ml to10 øg/ml. 
 
                                                                                    Table 12: Evaluation of injection 
Sr. 
No. 
Mixed 
Blend 
Appearance Clarity Test Leakage 
Test 
pH of Aq. 
Injection 
Viscosity of Aq. 
Injection (cp) 
1 B-19 Clear Transparent Clear Passes 5.6 1.52 
2 B-21 Clear Transparent Clear Passes 6.2 1.72 
3 B-22 Clear Transparent Clear Passes 6.8 1.67 
4 B-23 Clear Transparent Clear Passes 7 1.59 
 
FT-IR Spectroscopy study Drug & Solubilizers 
The infrared spectrum of Ofloxacin was concordant with the 
reference spectrum of Ofloxacin and shows all the major peaks as 
shown in Fig. no. 3  the procured sample is pure and can be used 
for further studies. And IR spectraÊs were recorded for Ofloxacin 
with combination of lignocaine Hydrochloride. Sodium Benzoate, 
Sodium Citrate, PEG-400, PVP-40000, Niacinamide, To study the 
compatibility of drug with excipients FTIR spectra of drug in 
combination with excipients in the form of formulation was studied.  
 
Table 13: Chemical stability B-19 
Time 
(days) 
% Drug remaining
 
2-8 0C 25 0C 40 0C 55 0C
0 100.0 100.0 100.0 100.0
7 92 87 83 79
14 87.3 79 77 63
21 78 72 68 52
28 69 58 - -
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  Figure15: Degradation Curve for the Formulation 
 
Table 14: Chemical Stability B-21 
Time 
(days) 
% Drug remaining 
 
2-8 0C 25 0C 40 0C 55 0C
0 100.0 100.0 100.0 100.0
7 96.4 94 93 82
14 89.3 85.6 82 69
21 80 78 76 60
28 73 68 - - 
 
All the above characteristic peaks of drug appear in the spectra of 
physical mixture at the same wave number indicating no 
modification and interaction between the drug and Solubilizer. 
Results of the drug interaction studies suggest that all the studied 
excipients are compatible with Ofloxacin recorded in fig no.  4 to 9. 
 
Figure 16:   Degradation Curve for the Formulation 
 
Table 15: Chemical Stability B-22 
Time 
(days) 
% Drug remaining 
 
2-8 0C 25 0C 40 0C 55 0C 
0 100.0 100.0 100.0 100.0 
7 93 83 78 67 
14 88 77 73 61 
21 76 72 61 56 
28 71 63 - - 
 
 
   Figure 17: Degradation Curve for the Formulation 
 
 
Table 16: Chemical Stability B-23 
 
Time 
(days) 
% Drug remaining 
 
2-8 0C 25 0C 40 0C 55 0C
0 100.0 100.0 100.0 100.0
7 91 81 76 67
14 82 74 68 61
21 71 64 55 51
28 63 54 - -
 
 
Figure 18: Degradation Curve for the Formulation 
 
DSC of Drug Sample 
 
The thermogram of Ofloxacin showed peak indicating the melting 
point of the drug is 268.75oC which is identically near to the melting 
point mentioned in standards. From obtained result it was 
concluded that drug was in pure form. DSC Curve shown in figure 
10. 
Physical Stability of Drug & Solubilizers 
 
All Drug & solubilizers were found to be stable & no interaction and 
result shown in table no. 2. 
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The solubility of Ofloxacin was increased by use of various 
solubilizers. The solubilizing power of different solubilizers could be 
ranked as Sodium benzoate > Tween 20> Niacinamide> 
Lignocaine HCl.> PEG 4000 > Propylene glycol > PEG 400> PEG 
40000 > ethanol. While the solubility of Ofloxacin was decreased 
by sodium citrate hence, it is clear that solubilizers may increase or 
decrease the solubility of drugs. Solubility recorded in table 3 and 
Solubility profile shown in figure 11. 
 
 
Table no.17 Observations of Soyabean Casein Digest Media 
Sr.no
. 
Formulation code Media used Observation Inference 
1 B-19 Soyabean casein 
Digest media 
No colony form Tested formulation showed No growth of 
Bacteria 
2 B-21 Soyabean casein 
Digest media 
No colony form Tested formulation showed No growth of 
Bacteria 
3 B-22 Soyabean casein 
Digest media 
No colony form Tested formulation showed  No growth of 
Bacteria 
4 B-23 Soyabean casein 
Digest media 
No colony   form Tested formulation showed No growth of 
Bacteria 
 
Table no.18 Observation of Sabouraud-dextrose Agar with Antibiotic 
Sr.no
. 
Formulation code Media used Observation Inference 
1 B-19 Sabouraud-dextrose 
agar 
No colony   form Tested formulation showed No growth of 
Fungi 
2 B-21 Sabouraud-dextrose 
agar 
No colony   form Tested formulation showed No growth of 
Fungi 
3 B-22 Sabouraud-dextrose 
agar 
No colony   form Tested formulation showed No growth of 
Fungi 
4 B-23 Sabouraud-dextrose 
agar 
No colony   form Tested formulation showed No growth of 
Fungi 
 
Solubility Determination of Drug in Aqueous Solution 
Mixed Blend Solubilizers (25% w/v) 
 
All 24 blend solubility was determined in mg/ml. In Blend no.1, 
3,4,5,8,9,10, 12,14,15,17,18,20,24 they are form precipitate (ppt) 
due presence of Sodium benzoate and lignocaine HCl. In Blend no. 
1 shows low solubility & Blend no. 21 shows high solubility. 
Solubility recorded in table no. 5 & profile shown in fig. no. 12. 
Determination of pH Dependent Solubility of Drug 
The solubility of Ofloxacin slightly decreased with increase in pH 
but it did not vary significantly with pH change. The solubility 
enhancement ratio at pH 2.4 was (as compared to solubility in 
distilled water) which was less than the enhancement in mixed 
blends. Thus, enhancement in solubility of Ofloxacin in mixed 
blends was not due to the effect of pH only. Solubility recorded in 
table no. 6 & profile shown in figure 13. 
Chromatographic Study of Solubilized Drug product 
From the table 7,   it is evident that all the spots in three blends 
correspond with the RF value of standard Ofloxacin drug. From the 
result of chromatography, it was concluded that there was no 
Complexation and/or interaction between drug and solubilizers. 
Optimization of Blend for preparation of injection 
Aqueous Injection of various blends shown in table 8 to 11. 
Evaluation of Aqueous Injection 
i)  Appearance and colour of formulation 
In which Appearance of Aqueous Injection of Ofloxacin show in fig. 
no. 14, and recorded in table 12. 
ii)  Determination of pH of the developed aqueous injection 
The pH of formulation of aqueous injection was measure 
satisfactory and recorded in table 12. 
iii) Accelerated stability studies 
From the results shown in tables 13 to 16 it is evident that the 
developed formulations of aqueous injection of Ofloxacin were not 
sufficiently stable at room temperature and refrigerated condition in 
all Blends. The shelf lives of formulations B-19, B-21, B-22 and B-
23 were found as 14 days, 21 days, 28 days and 7 days 
respectively. To overcome the problem of instability of formulation, 
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it may be formulated as dry powder for injection by using the solid 
solubilizing agents & Degradation curve shown in fig. no. 15 to 18. 
iv) Clarity testing of aqueous injection 
The Clarity test of given Aqueous Injection of Ofloxacin was found 
to be clear. Shown in table no. 12. 
v) Leakage test of aqueous formulation 
The leakage test of given Aqueous Injection of Ofloxacin was found 
to be Passes & result shown in table. no. 12. 
vi) Viscosity of aqueous injection 
The result show in table no.12, that viscosity was found to be 
satisfactory. 
vii) Sterility test for aqueous injection as per I.P. 
There is No colony formation on the membrane filter after filtration 
that shows there is No presence of bacteria and fungi & result 
shown in table no. 17 to 18. 
Summary and Conclusion 
The objective of present work was to explore the novel application 
of mixed solvency technique in the injection formulation of poorly 
soluble drugs and to reduce concentration of individual solubilizers 
(used for solubility enhancement) to minimize the toxic effects of 
solubilizers. In most of the methods of Solubilization, high 
concentration of an additive (hydrotropic 
agent/cosolvents/surfactants/etc.) is required to produce an 
appreciable increase in solubility of a poorly soluble drug. In this 
case, the solubilizing agent employed to give a desirable solubility 
for the poorly soluble drug may produce its own toxicity. In the 
present study, practically water insoluble drug Ofloxacin were 
selected as model drugs. These drugs were tried to solubilize by 
employing the combination of physiologically compatible 
solubilizers in attempt to prepare their parenteral formulations 
(aqueous injection of Ofloxacin). 
In the present work, the procured Ofloxacin drug samples were 
characterized by various tests. Melting point was determined by 
open capillary method and DSC the melting points were found to 
be 253-257ÀC for Ofloxacin respectively. Spectrophotometric 
method was used to analyze the drugs; Ofloxacin showed peak at 
287.6 nm was selected for analysis. FTIR spectroscopy was 
performed for further characterization of drugs, prior to use in the 
formulation. The procured samples of drugs were found to be in 
confirmation with the reported literature and were thus, used for 
further studies. 
In preformulation studies, calibration curves of drugs were 
prepared in various media, viz., ethanol, distilled water and distilled 
water in presence of solubilizers. The correlation coefficients 
obtained were very close to one which confirmed that the Beer- 
LambertÊs law was obeyed in concentration range of 2-10 øg/ml 
and solubilizer range 10-50 mcg/ml for drug solutions in all media 
for both Ofloxacin. The UV interference studies (in aqueous media 
for Ofloxacin) showed that none of the selected solubilizers 
interfere in UV estimation of drugs. Solubility studies of Ofloxacin 
were performed in various media, viz., Distilled water, 25% 
aqueous solution containing individual solubilizers (Sodium 
Benzoate, Niacinamide, PEG 4000, PEG 400, Lignocaine 
Hydrochloride, Propylene Glycol, Tween 20, PVP- 40000) and 
aqueous solutions of mixed blends of solubilizers. The Ofloxacin 
was found to be practically insoluble in water having solubility 
0.11mg/ml. There was appreciable enhancement in solubility of 
Ofloxacin in aqueous solutions containing individual solubilizers 
and combination of solubilizers. The solubilites in aqueous 
solutions of individual solubilizers, PEG 4000, PEG 400, 
niacinamide, Propylene glycol, PVP- 40000, sodium benzoate, 
lignocaine hydrochloride, Ethanol were found to be 2.55 mg/ml, 
1.97 mg/ml, 3.25 mg/ml, 2.28 mg/ml, 1.69 mg/ml, 4.75 mg/ml, 2.66 
mg/ml and 1.55 mg/ml respectively. These results showed 
synergistic enhancement in solubility when the solubilizers were 
used in mixed blends. To check the influence of pH on the 
Solubility of Ofloxacin solubilityÊs of Ofloxacin were determined in 
different pH solution. Ofloxacin solubility slightly of Ofloxacin 
decreases with increase in pH. From the results of solubility 
studies, mixed blends in which solubility of Ofloxacin was more 
than 4 mg/ml were selected to develop the injections, such mixed 
blends were B-19, B-21, B-22 and B-23. The injection formulations 
of various strengths were developed based on solubility of 
Ofloxacin in individual mixed blends. Prepared formulations were 
sterilized by membrane filtration method flushed with nitrogen and 
filled in glass vials. The formulations when subjected to accelerated 
stability studies showed rapid degradation of drug, the shelf lives of 
formulations were predicted as 14 days, 21 days, 28 days and 7 
days for B-19, B-21, B-22 and B-23 respectively. From the results 
of stability studies and literatures it was concluded that Ofloxacin is  
sufficiently stable in aqueous media, so it was decided to formulate 
Ofloxacin as Aqueous injection by using solubilizers. The clarity 
and leakage test were passes found as per I.P. Standard. Viscosity 
was measure by Brookfield viscometer various blend B-19, B-21, 
B-22, B-23 were respectively 1.52, 1.72, 1.67 and 1.59 in 
centipoises. And Sterility was passes & No fungi or bacteria 
presence of due to unhygienic condition at small scale production 
of aqueous injection of Ofloxacin. Thus, above findings supports 
that by using novel technique of mixed solvency the required 
solubility can be achieved, solubilizers can be selected in safer 
range and dosage forms can be developed which are expected to 
show good stability also. The above research findings showed that, 
a stable aqueous injection formulation containing Ofloxacin were 
successfully developed. There is good scope for other poorly 
water-soluble drugs to develop their aqueous formulation by the 
use of combination of suitable solubilizers are known to safe 
hence, toxicities/safety related issues may not rise, suggesting the 
adoptability for large scale manufacturing . The proposed 
techniques would be economical convenient and safe. Thus, the 
study opens the chances of preparing such aqueous formulation of 
poorly-water soluble drugs. 
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